Financhill
Buy
58

WGS Quote, Financials, Valuation and Earnings

Last price:
$80.99
Seasonality move :
51.28%
Day range:
$74.75 - $78.10
52-week range:
$2.47 - $89.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.65x
P/B ratio:
10.40x
Volume:
138.8K
Avg. volume:
537.1K
1-year change:
2497.32%
Market cap:
$2.1B
Revenue:
$202.6M
EPS (TTM):
-$3.11

Analysts' Opinion

  • Consensus Rating
    GeneDx Holdings has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, GeneDx Holdings has an estimated upside of 4.44% from its current price of $77.40.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $77.40.

Fair Value

  • According to the consensus of 4 analysts, GeneDx Holdings has 4.44% upside to fair value with a price target of -- per share.

WGS vs. S&P 500

  • Over the past 5 trading days, GeneDx Holdings has underperformed the S&P 500 by -5.07% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • GeneDx Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • GeneDx Holdings has grown year-over-year revenues for 3 quarters straight. In the most recent quarter GeneDx Holdings reported revenues of $76.9M.

Earnings Growth

  • GeneDx Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter GeneDx Holdings reported earnings per share of -$0.31.
Enterprise value:
2.1B
EV / Invested capital:
8.04x
Price / LTM sales:
7.65x
EV / EBIT:
--
EV / Revenue:
7.72x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-34.37x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$158.9M
Return On Assets:
-20.58%
Net Income Margin (TTM):
-31.25%
Return On Equity:
-38.37%
Return On Invested Capital:
-32.02%
Operating Margin:
-10.12%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $231.1M $206.5M $267.2M $53.3M $76.9M
Gross Profit -$13.2M $42.9M $158.9M $25.3M $47.8M
Operating Income -$458.6M -$259.3M -$57.7M -$34.7M -$7.8M
EBITDA -$309.3M -$200.5M -$59.1M -$26M -$1.9M
Diluted EPS -$31.09 -$35.49 -$3.11 -$1.64 -$0.31
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets -- $538.5M $306.6M $171.8M $186M
Total Assets -- $603.4M $829M $417.3M $408.8M
Current Liabilities -- $71.4M $162.3M $68.4M $77.3M
Total Liabilities -- $212.1M $267.7M $163M $204.3M
Total Equity -- $391.3M $561.3M $254.3M $204.5M
Total Debt -- $11M $10.7M $6.3M $52M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$306.5M -$214.9M -$55.2M -$41.2M -$4.4M
Cash From Investing -$146.2M -$41.7M -$34.5M -$27.1M -$7.8M
Cash From Financing $196.2M $139.2M $60.2M -$911K $14M
Free Cash Flow -$325.7M -$221.1M -$60M -$41.3M -$5M
WGS
Sector
Market Cap
$2.1B
$46.1M
Price % of 52-Week High
86.86%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-2.04%
-0.6%
1-Year Price Total Return
2497.32%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $77.31
200-day SMA
Buy
Level $37.96
Bollinger Bands (100)
Buy
Level 36.31 - 74.41
Chaikin Money Flow
Sell
Level -72M
20-day SMA
Buy
Level $76.76
Relative Strength Index (RSI14)
Buy
Level 53.95
ADX Line
Sell
Level 25.65
Williams %R
Neutral
Level -50.8276
50-day SMA
Buy
Level $72.82
MACD (12, 26)
Buy
Level 1.33
25-day Aroon Oscillator
Buy
Level 48
On Balance Volume
Neutral
Level 3.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-4.6256)
Sell
CA Score (Annual)
Level (-1.8418)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.7553)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.

Stock Forecast FAQ

In the current month, WGS has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The WGS average analyst price target in the past 3 months is --.

  • Where Will GeneDx Holdings Stock Be In 1 Year?

    According to analysts, the consensus estimate is that GeneDx Holdings share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About GeneDx Holdings?

    Analysts are divided on their view about GeneDx Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GeneDx Holdings is a Sell and believe this share price will drop from its current level to --.

  • What Is GeneDx Holdings's Price Target?

    The price target for GeneDx Holdings over the next 1-year time period is forecast to be -- according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is WGS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for GeneDx Holdings is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of WGS?

    You can purchase shares of GeneDx Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GeneDx Holdings shares.

  • What Is The GeneDx Holdings Share Price Today?

    GeneDx Holdings was last trading at $80.99 per share. This represents the most recent stock quote for GeneDx Holdings. Yesterday, GeneDx Holdings closed at $77.40 per share.

  • How To Buy GeneDx Holdings Stock Online?

    In order to purchase GeneDx Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 26

Power Solutions International [PSIX] is down 0.77% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.24% over the past day.

Buy
75
SMLR alert for Dec 26

Semler Scientific [SMLR] is down 1.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock